MedTrace Logo

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

NCT03892096 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2024-02-07

No results posted yet for this study

Summary

Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in stage IV non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BC).

Conditions

Interventions

DIAGNOSTIC_TEST

Blood-based cell-free cfDNA qPCR assay

Up to 30mL of blood via venipuncture

Sponsors & Collaborators

  • Cadex Genomics

    lead INDUSTRY

Principal Investigators

  • Christer Svedman, M.D. Ph.D. · Cadex Genomics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2023-11-15
Completion
2024-02-06

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03892096 on ClinicalTrials.gov